|Day Low/High||2.31 / 2.57|
|52 Wk Low/High||0.64 / 1.99|
Here's a technical look at how to trade several under $10 stocks that could trigger big breakout trades soon.
- New patent application filed for hCDR1 in the treatment of Sjogren's syndrome
Company to file IND with FDA and plans to commence trial in 2016
World renowned expert in the treatment of lupus with over 60 published articles and extensive clinical trial experience
Fortifies patent position in Europe, where Phase 2 trial is expected to commence in 2016
SME status supports XTL's European clinical program for hCDR1 in the treatment of lupus and its upcoming Phase 2 trial
Lead asset addresses unmet need in market projected to reach $4 billion
Collaborating to bring an effective treatment to market for the 1.5 million Americans living with lupus
Successful outcome of FDA guidance includes BILAG as the primary efficacy endpoint, patient inclusion criteria, and patient population for safety requirements for marketing approval
XTL to formulate hCDR1 using Captisol® in its advanced clinical studies
hCDR1 addresses significant unmet medical need for lupus, a chronic and complex disease for which there is currently no cure
TheStreet highlights 3 stocks pushing the Health Care sector lower today.
TheStreet highlights 3 stocks pushing the Drugs industry lower today.